11th World Affordable Medicine Congress

11th World Affordable Medicine Congress 7 - 8 February 2017, Barcelona, Spain.
The Annual World Affordable Medicine Congress comes to Barcelona, this is the newly rebranded World Generic Medicines Congress and Biosimilar Drug Development World. For 11 years, the biggest and best in the industry. Through a series of interactives presentation, speed networking and stream sessions, the congress will provide fresh insights into future market trends, innovative commercial strategies and opportunities for growth for affordable medicines.

Don't miss out the opportunity to share your experience and network with senior and board level executives working in generic and biosimilar organisations.

Don't miss your chance to hear from:

  • Klaus Martin, Chief Scientific Officer, Polpharma Biologics
  • Matthew Turner, Global Medical Director Biosimilars, Merck
  • Bernd Liedert, Sr.Clinical Program Leader Biosimilars, Boehringer Ingelheim
  • Isabel Afonso, Head of Global Commercial Strategy and member of the Sandoz Executive Committee, Sandoz
  • Steinar Madsen, Medical Director, Norwegian Medicines Agency
  • Adrian Thomas, Vice President of Health Economics & Market Access, Janssen North America

Download the brochure now to see who's speaking.

World Pharma News readers can benefit from an exclusive 10% discount. Quote discount code CGNN

For further information, please visit:
http://www.healthnetworkcommunications.com/conference/affordable-medicines/

About World Affordable Medicine Congress
The World Affordable Medicine Congress Europe brings together two world class events - World Generic Medicines Congress and Biosimilar Drug Development World - that have been central to the industry’s business and networking needs for over 10 years. Over 2000 business leaders participants have benefited from this series since 2007.

The event unites senior executives from the generic and biosimilar industry to provide fresh insights into future market trends, innovative commercial strategies and opportunities for growth for affordable medicines.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...